Delivery Order HHSN261201500018I-75N91018F00008
Award Date
9/17/18
Potential Completion Date
6/16/23
Potential Value
$775K
Federal Agency
National Cancer Institute
Ultimate Awardee
University Of Texas System
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $849,016 contract, which runs from September 17, 2018 to December 16, 2022, supports the "Rank Ligand Inhibition - A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer" project under the Preclinical...
This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
The National Cancer Institute awarded a Firm Fixed Price Delivery Order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, valued at $1,121,090.00. The contract is part of the PREVENT Preclinical Drug Development Program and supports preclinical efficacy and intermediate endpoint biomarker studies targeting the PARP pathway for the prevention of breast cancer. The contract has a period of performance through May 31, 2026 and is not set...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
This federal contract award from the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) is for the "CANCER PREVENTION BY ALPHA ENOLASE VACCINATION" project, which is part of the NCI's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" initiative. The $547,718.84 firm fixed price delivery order contract was awarded on September 15, 2016 with a completion date of February 14, 2020. MD...
This is a firm fixed-price delivery order contract awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "Targeted Casein Kinase Inhibition as a Breast Cancer Prevention" research project. The $505,743.00 contract, which has no set-aside designation, was awarded on June 20, 2017 and is scheduled for completion by December 31, 2019. The contract falls under...
This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14,...
The University of Texas M.D. Anderson Cancer Center has been awarded a $632,712 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for the task of conducting preclinical efficacy and intermediate biomarker studies to develop an induced pluripotent stem cell-based vaccine for the...